CrushSCI.com
提供学术论文选刊润色服务
INVESTIGATIONAL NEW DRUGS 期刊封面 医学
返回期刊列表

Review Cycle Records

INVESTIGATIONAL NEW DRUGS

Springer SCIE 非OA
2026新锐 3区2025中科院 3区2025 JCR Q2
74.1平均天数
69中位天数
27最短天数
160最长天数
1012025发文量

Paper Review Records

全部论文审稿周期

15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

27 天

Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330

作者Hamid Bellout

作者单位1. Northern Illinois University, DeKalb, USA

PDF源文件 DOI 网页
89 天

Preclinical evaluation and mechanistic analysis of antitumor effects of the novel anti-CD147 antibody DS-1471a in liver cancer models

作者Hiroshi Yuita; Sadanori Watanabe; Jun Tsukada; Yoshikazu Johmura; Sae Aratani; Hirokazu Ishikawa; Ryuichi Nakamura; Miki Yokoyama; Mari Hashimoto; Hideo Yukinaga; Huynh The Hung; Makoto Nakanishi; Keisuke Fukuchi

作者单位1. Translational Science Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 2. Discovery Research Laboratories I, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 3. Division of Cancer and Senescence Biology, Cancer Research Institute, Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Japan; 4. Division of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 5. Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 6. Translational Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 7. Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 8. Daiichi Sankyo Inc., Basking Ridge, USA; 9. Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore

PDF源文件 DOI 网页
76 天

A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer

作者Fengting Yan; Marcia Cruz-Correa; Jennifer Specht; Edward Wenge Wang; Jinyu Lu; Hatem Soliman; Amy Jackson-Fisher; Szu-Yu Tang; Sibo Jiang; Christophe Le Corre; Meng Li; David Sommerhalder

作者单位1. Swedish Cancer Institute, Seattle, USA; 2. Pan American Center for Oncology Trials, San Juan, USA; 3. Fred Hutchinson Cancer Center, Seattle, USA; 4. City of Hope Comprehensive Cancer Center, Duarte, USA; 5. Montefiore Einstein Comprehensive Cancer Center, Bronx, USA; 6. Moffitt Cancer Center, Tampa, USA; 7. Pfizer, San Diego, USA; 8. Pfizer, South San Francisco, USA; 9. NEXT Oncology, San Antonio, USA

PDF源文件 DOI 网页
136 天

Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer

作者Jordi Rodon; Bert O’Neil; Christopher Lim; Natraj R. Ammakkanavar; Carlos Torrado; Kazuaki Matsuoka; Hiroshi Hirai; Akihiro Miura; Bailey Anderson; Leah Jin; Nanae Hangai; Amanda Long; Volker Wacheck; Lee Rosen

作者单位1. MD Anderson Cancer Center, Houston, USA; 2. Community Health Network, Indianapolis, USA; 3. Division of Hematology-Oncology, UCLA, Los Angeles, USA; 4. Taiho Pharmaceutical Co. Ltd, Tokyo, Japan; 5. Taiho Oncology, Inc., Princeton, USA

PDF源文件 DOI 网页
88 天

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer

作者Khobe Chandran; Christina Guo; Simon Pacey; Guillermo Villacampa; Ruth Matthews; Toby Prout; Joan Fernandes; Alison Turner; Mona Parmar; Ruth Riisnaes; Ana Ferreira; Suzanne Carreira; Claudia Bertan; Mateus Crespo; Ines Figueiredo; Wei Yuan; Denisa Bogdan; Florence Raynaud; Ruth Ruddle; Bianca Calì; Martino Maddalena; Arianna Calcinotto; Christina Yap; Adam Sharp; Andrea Alimonti; Johann De Bono; Alec Paschalis

作者单位1. Institute of Cancer Research, London, UK; 2. The Royal Marsden NHS Foundation Trust, London, UK; 3. Department of Oncology, School of Clinical Medicine, University of Cambridge, Cambridge, UK; 4. Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge, UK; 5. Institute of Oncology Research (IOR), Bellinzona, Switzerland; 6. Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland; 7. Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; 8. Department of Health Sciences and Technology, Eidgenössische Technische Hochschule Zürich (ETH), Zurich, Switzerland; 9. Department of Medicine, University of Padova, Padua, Italy

PDF源文件 DOI 网页
38 天

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors

作者Alejandro Falcón; Gregory M. Cote; Javier Molina-Cerrillo; Axel Le Cesne; Pedro Rocha; Bruno Bockorny; David Paez; Javier Martin-Broto; Sant P. Chawla; Sara Martinez; Carmen Kahatt; Vicente Alfaro; Mariano Siguero; Javier Jimenez; Ana Custodio; Vicente Alonso-Orduña; Carlos López; Attila Kollár; Juan José Soto-Castillo; Luis Paz-Ares

作者单位1. Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain; 2. Servicio de Oncología Médica, Hospital Universitario Virgen del Rocio, Seville, Spain; 3. Medical Oncology Department, Mass General Brigham Cancer Institute, Boston, USA; 4. Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; 5. Medical Oncology Department, Institute Gustave Roussy, Villejuif, France; 6. Medical Oncology Department, Vall d’ Hebrón University Hospital, Barcelona, Spain; 7. Medical Oncology Department, Beth Israel Deaconess Medical Center, Boston, USA; 8. Medical Oncology Department, Sant Pau, CIBERER, Barcelona, Spain; 9. Medical Oncology Department, Fundación Jiménez Díaz University Hospital General de Villalba, and Instituto deInvestigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJDUAM), Madrid, Spain; 10. Sarcoma Oncology Research Center, Santa Monica, USA; 11. Clinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain; 12. Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; 13. Medical Oncology Department, Hospital Universitario Miguel Servet, Saragossa, Spain; 14. Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, UNICAN, Santander, Spain; 15. Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 16. Medical Oncology Department, START Madrid CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain; 17. Medical Oncology Department, Hospital Universitario, Madrid, Spain

PDF源文件 DOI 网页
34 天

Class-level DILI saturation and hERG-driven risk stratification among 2024–2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis

作者Nihan Küçük Yılmaz; Veysel Baskın

作者单位1. Department of Medical Pharmacology, Faculty of Medicine, Yalova University, Yalova, Turkey; 2. Department of Medical Pharmacology, Faculty of Medicine, Hitit University, Çorum, Turkey

PDF源文件 DOI 网页
34 天

Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours

作者Rosalind Glasspool; Sarah Patricia Blagden; Michelle Lockley; Elaine McCartney; Carol Evans; Fiona Thomson; Jennifer Brown; Laura Spiers; Chantevy Pou; Liz-Anne Lewsley; Iain A. McNeish; T.R. Jeffry Evans

作者单位1. Beatson West of Scotland Cancer Centre and School of Cancer Sciences, University of Glasgow, Glasgow, UK; 2. Early Phase Clinical Trials Unit, Churchill Hospital, Oxford University Hospitals, Oxford, UK; 3. Centre for Cancer Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK; 4. Cancer Division, University College London Hospital, London, UK; 5. Glasgow Oncology Clinical Trials Unit, University of Glasgow, Glasgow, UK; 6. The Translational Pharmacology & Immunology Laboratory, School of Cancer Sciences, University of Glasgow, Glasgow, UK; 7. Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK

PDF源文件 DOI 网页
37 天

Prostate cancer cells’ growth is decreased by novel MYC inhibitors

作者Bita Nickkholgh; Joseph McGrath; Sivanandane Sittadjody; Jay Chauhan; Kwan-Young Jung; Steven Fletcher; K. C. Balaji

作者单位1. Wake Forest Institute for Regenerative Medicine (WFIRM), Wake Forest University School of Medicine, Winston-Salem, USA; 2. Department of Physiology-Pharmacology, Wake Forest University School of Medicine, Winston-Salem, USA; 3. Department of Urology, University of FL College of Medicine – Jacksonville, Jacksonville, USA; 4. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, USA

PDF源文件 DOI 网页
126 天

Spatial blueprint of colorectal cancer identifies Hypoxic CAF program that orchestrates Go-or-Grow decisions and predicts outcomes

作者Mingkai Chen; Juan Yang; Jin Wang; Guangrun Du; Lida Zhang

作者单位1. Department of Gastroenterology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China; 2. Department of Gastroenterology, Zhengzhou Yihe Hospital Affiliated to Henan University, Zhengzhou, China

PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿96.4 天

中位数77 天

Contact CrushSCI

联系 CrushSCI

扫码添加微信,或留下手机号/微信号,我们将与你确认稿件阶段、编辑需求和投稿计划。

当前选择:论文编辑服务

也可以预留联系方式

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。